Literature DB >> 31666350

Targeting of β-Catenin Reverses Radioresistance of Cervical Cancer with the PIK3CA-E545K Mutation.

Wei Jiang1,2, Yutuan Wu1,2, Tiancong He1,2, Hanting Zhu2,3, Guihao Ke1,2, Libing Xiang4,2, Huijuan Yang4,2.   

Abstract

This study aims to explore whether E545K, the most common hotspot mutation of PIK3CA in cervical cancer, confers radioresistance to cervical cancer cells, to demonstrate the underling mechanism, and to develop the effective targets. SiHa and MS751 cells with PIK3CA-WT and PIK3CA-E545K were established by lentiviral transfection. The radiosensitivity was assessed by colony formation, cell cycle, cell apoptosis, DNA damage, and repair assay. The growth and immunohistochemical assay of xenograft tumor-related toxicity were evaluated in vivo It was indicated that more cells with PIK3CA-E545K arrested in S phase. Irradiation (IR) led to more survival percentage, less apoptosis, fewer pH2A.X foci, and higher expression of Chk1/2 in SiHa and MS751 cells bearing PIK3CA-E545K. Mechanically, AKT/GSK3β/β-catenin pathway was highly activated, and more β-catenin was found accumulated in nucleus in cells with PIK3CA-E545K after IR. Furthermore, targeting β-catenin by shRNA or XAV939 enhanced IR sensitivity in cells with PIK3CA-WT and PIK3CA-E545K, whereas it was more notably in the latter. β-Catenin shRNA and XAV939 increased IR-mediated inhibition of colony formation with highly activated p53/bcl2/bax pathway. XAV939 enhanced IR-caused apoptosis, DNA damage, overcame S-phase arrest, DNA repair and reversed β-catenin nuclear accumulation in MS751 cells with PIK3CA-E545K. In vivo, XAV939 enhanced the radiosensitivity of cervical cancer xenografts with PIK3CA-E545K with invisible viscera toxicity. The findings demonstrate that cervical cancer cells with PIK3CA-E545K are resistant to IR by enhancing the expression and nuclear accumulation of β-catenin. Targeting β-catenin reverses the radioresistance, which suggests possible areas for preclinical research on β-catenin inhibition for strengthening the radiosensitivity of cervical cancer. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31666350     DOI: 10.1158/1535-7163.MCT-19-0309

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  6 in total

Review 1.  The role of PI3K/AKT signaling pathway in gallbladder carcinoma.

Authors:  Zeyu Wu; Xiao Yu; Shuijun Zhang; Yuting He; Wenzhi Guo
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

Review 2.  The Role of LncRNAs in the Regulation of Radiotherapy Sensitivity in Cervical Cancer.

Authors:  Hanqun Zhang; Chunju Fang; Zhiyu Feng; Tingting Xia; Liang Lu; Min Luo; Yanping Chen; Yuncong Liu; Yong Li
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

3.  Discovery and Validation of Serum Autoantibodies Against Tumor-Associated Antigens as Biomarkers in Gastric Adenocarcinoma Based on the Focused Protein Arrays.

Authors:  Qian Yang; Jiejie Qin; Guiying Sun; Cuipeng Qiu; Di Jiang; Hua Ye; Xiao Wang; Liping Dai; Jicun Zhu; Peng Wang; Jianying Zhang
Journal:  Clin Transl Gastroenterol       Date:  2020-12-21       Impact factor: 4.488

4.  PIK3CA Mutations in Diffuse Gliomas: An Update on Molecular Stratification, Prognosis, Recurrence, and Aggressiveness.

Authors:  Cheila Brito; Ana Tomás; Ana Azevedo; Susana Esteves; Manuela Mafra; Lúcia Roque; Marta Pojo
Journal:  Clin Med Insights Oncol       Date:  2022-01-06

5.  Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing.

Authors:  Ling Qiu; Hao Feng; Hailin Yu; Ming Li; Yana You; Shurong Zhu; Wenting Yang; Hua Jiang; Xin Wu
Journal:  Genes (Basel)       Date:  2022-01-31       Impact factor: 4.096

6.  Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma.

Authors:  Weiwei Liu; Lu Zheng; Rongguiyi Zhang; Ping Hou; Jiakun Wang; Linquan Wu; Jing Li
Journal:  Mol Cancer       Date:  2022-03-11       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.